Rallybio to merge into Avenzo Therapeutics in $215M reverse-triangular deal
Rhode Island-based Rallybio Corporation announced a definitive agreement to acquire Avenzo Therapeutics in an all-stock reverse-triangular merger combined with $215 million in concurrent private financing. The combined company will be renamed Avenzo Therapeutics and trade on Nasdaq as AVZO. Pre-transaction Rallybio equityholders will own about 2.8 percent of the combined company.
